Tyra Biosciences Inc (TYRA)
17.80
-0.23
(-1.28%)
USD |
NASDAQ |
May 09, 16:00
17.80
0.00 (0.00%)
After-Hours: 20:00
Tyra Biosciences Cash from Operations (TTM): -50.14M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -50.14M |
| September 30, 2023 | -48.59M |
| June 30, 2023 | -43.65M |
| March 31, 2023 | -51.21M |
| December 31, 2022 | -50.28M |
| Date | Value |
|---|---|
| September 30, 2022 | -47.33M |
| June 30, 2022 | -40.70M |
| March 31, 2022 | -27.99M |
| December 31, 2021 | -23.74M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-51.21M
Minimum
Mar 2023
-23.74M
Maximum
Dec 2021
-42.63M
Average
-47.33M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | -4.131M |
| Palatin Technologies Inc | -26.54M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -19.00M |
| Oragenics Inc | -7.291M |